Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Competition in pharmaceuticals: more product- than price-oriented?

Literature DB >> 28993950

Competition in pharmaceuticals: more product- than price-oriented?

Livio Garattini¹, Anna Padula².

Abstract

Mesh：

Year: 2018 PMID： 28993950 DOI： 10.1007/s10198-017-0932-4

Source DB: PubMed Journal: Eur J Health Econ ISSN： 1618-7598

× No keyword cloud information.

15 in total

1. The German experience in reference pricing.

Authors: G Giuliani; G Selke; L Garattini
Journal: Health Policy Date: 1998-04 Impact factor: 2.980

Review 2. Modeling in pharmacoeconomic studies: funding sources and outcomes.

Authors: Livio Garattini; Daniela Koleva; Gianluigi Casadei
Journal: Int J Technol Assess Health Care Date: 2010-07 Impact factor: 2.188

3. Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?

Authors: Livio Garattini; Alessandro Curto; Nick Freemantle
Journal: Pharmacoeconomics Date: 2016-05 Impact factor: 4.981

4. Reference drug programs: effectiveness and policy implications.

Authors: Sebastian Schneeweiss
Journal: Health Policy Date: 2006-06-13 Impact factor: 2.980

5. Patent nonsense: evidence tells of an industry out of social control.

Authors: Henry Mintzberg
Journal: CMAJ Date: 2006-08-15 Impact factor: 8.262

6. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis.

Authors: Livio Garattini; Dante Cornago; Paola De Compadri
Journal: Health Policy Date: 2006-11-27 Impact factor: 2.980

7. Between pharmaceutical patents and European patients: is a compromise still possible?

Authors: Livio Garattini; Anna Padula
Journal: Expert Opin Ther Pat Date: 2017-07-10 Impact factor: 6.674

8. After thalidomide - do we have the right balance between public health and intellectual property.

Authors: Peter Feldschreiber; Alasdair Breckenridge
Journal: Rev Recent Clin Trials Date: 2015

Review 9. Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

Authors: Brian Godman; William Shrank; Bjorn Wettermark; Morten Andersen; Iain Bishop; Thomas Burkhardt; Kristina Garuolienè; Marija Kalaba; Ott Laius; Roberta Joppi; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; F Cankat Tulunay; Kamila Wendykowska; Corinne Zara; Lars L Gustafsson
Journal: Pharmaceuticals (Basel) Date: 2010-08-05

10. From adaptive licensing to adaptive pathways: delivering a flexible life-span approach to bring new drugs to patients.

Authors: H-G Eichler; L G Baird; R Barker; B Bloechl-Daum; F Børlum-Kristensen; J Brown; R Chua; S Del Signore; U Dugan; J Ferguson; S Garner; W Goettsch; J Haigh; P Honig; A Hoos; P Huckle; T Kondo; Y Le Cam; H Leufkens; R Lim; C Longson; M Lumpkin; J Maraganore; B O'Rourke; K Oye; E Pezalla; F Pignatti; J Raine; G Rasi; T Salmonson; D Samaha; S Schneeweiss; P D Siviero; M Skinner; J R Teagarden; T Tominaga; M R Trusheim; S Tunis; T F Unger; S Vamvakas; G Hirsch
Journal: Clin Pharmacol Ther Date: 2015-02-04 Impact factor: 6.875

4 in total

4. Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate.

Authors: Jeewon Park; SeungJin Bae; Tae-Jin Lee; Kyung-Bok Son
Journal: Front Pharmacol Date: 2020-03-06 Impact factor: 5.810